CHIASMA will develop, refine, apply and integrate innovative testing strategies, including computational and experimental methods, to enable risk assessment of chemicals and materials. The approaches will be 3R-conform using methods selected for their human relevance in cases of exposure. CHIASMA started in January 2024 and will run for 4 years.

Project goals

• Develop and refine innovative testing strategies to demonstrate their relevance and transferability in academic and industrial settings.
• Apply a battery of innovative testing strategies in DEMO-case studies addressing the toxicity of PFAS, nano-pesticides and 2D materials.
• Integration of innovative testing strategies into a safe and sustainable by design (SSbD) framework to support REACH and CLP.
• Drafting documentation and collection of data using the FAIR principle to enable maximal impact of the project output for scientific and regulatory purposes.

Consortium

The partners of the CHIASMA consortium are a diverse group of experts from large companies, small enterprises, institutes and academia. They bring together knowledge concerning various scientific disciplines (experimental, biological and chemical modelling), hazard identification and risk assessment to stimulate the implementation of consortium output by policymakers and industry.

Role of RIVM

RIVM has a leading role in the assessment of technology transferability between the various consortium partners and will be involved in stakeholder engagement concerning compliance of the proposed technologies into concrete risk assessment approaches. RIVM will aim to connect science to policy and survey transfer of knowledge within the consortium, but also between relevant (inter)national collaboration to enable maximal impact of the project.  Coordinator at RIVM:  Prof. F.R. Cassee.

Funding

CHIASMA has received funding from the European Union’s Horizon Europe Research and Innovation Programme under grant agreement No. 101137613.